iTANK: a nuniversal technology to boost the efficacy of CAR T cell therapies by inducing dual mode-of-actio

ended

Elicera developed a universally compatible technology platform called iTANK (ImmunoTherapies Activated with NAP for efficient Killing) to enhance the efficacy of current and under development CAR-T cell therapies by inducing a dual mechanism-of-action in the treatment of lymphomas and solid tumours. Elicera’s iTANK platform can circumvent major challenges of CAR-T cells in the treatment of solid tumours, such as antigen heterogenicity, local immunosuppression, and CAR T-cell exhaustion. As such, the iTANK platform has a potential to revolutionise the landscape of the immuno-oncology Our innovation arms CAR-T cells with NAP from H.pylori which induces a pro-inflammatory microenvironment and activates the patient’s own CD8+ killer T-cells against the whole repertoire of relevant tumour antigen targets. When tumour cells are killed, NAP-activated dendritic cells can take up tumour-associated antigens and prime killer T-cells against these antigens overcoming problems for CAR-T therapy.